Literature DB >> 27601679

Sufficient trial size to inform clinical practice.

Charles F Manski1, Aleksey Tetenov2.   

Abstract

Medical research has evolved conventions for choosing sample size in randomized clinical trials that rest on the theory of hypothesis testing. Bayesian statisticians have argued that trials should be designed to maximize subjective expected utility in settings of clinical interest. This perspective is compelling given a credible prior distribution on treatment response, but there is rarely consensus on what the subjective prior beliefs should be. We use Wald's frequentist statistical decision theory to study design of trials under ambiguity. We show that ε-optimal rules exist when trials have large enough sample size. An ε-optimal rule has expected welfare within ε of the welfare of the best treatment in every state of nature. Equivalently, it has maximum regret no larger than ε We consider trials that draw predetermined numbers of subjects at random within groups stratified by covariates and treatments. We report exact results for the special case of two treatments and binary outcomes. We give simple sufficient conditions on sample sizes that ensure existence of ε-optimal treatment rules when there are multiple treatments and outcomes are bounded. These conditions are obtained by application of Hoeffding large deviations inequalities to evaluate the performance of empirical success rules.

Keywords:  clinical trials; medical decision making; near optimality; sample size

Mesh:

Year:  2016        PMID: 27601679      PMCID: PMC5035895          DOI: 10.1073/pnas.1612174113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  10 in total

1.  ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group.

Authors: 
Journal:  Stat Med       Date:  1999-08-15       Impact factor: 2.373

2.  Addressing uncertainty in medical cost-effectiveness analysis implications of expected utility maximization for methods to perform sensitivity analysis and the use of cost-effectiveness analysis to set priorities for medical research.

Authors:  D Meltzer
Journal:  J Health Econ       Date:  2001-01       Impact factor: 3.883

Review 3.  Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment.

Authors:  A Hróbjartsson; P C Gøtzsche
Journal:  N Engl J Med       Date:  2001-05-24       Impact factor: 91.245

4.  The ethics of the placebo in clinical practice.

Authors:  P Lichtenberg; U Heresco-Levy; U Nitzan
Journal:  J Med Ethics       Date:  2004-12       Impact factor: 2.903

5.  An economic approach to clinical trial design and research priority-setting.

Authors:  K Claxton; J Posnett
Journal:  Health Econ       Date:  1996 Nov-Dec       Impact factor: 3.046

6.  Understanding statistical hypothesis testing.

Authors:  Philip Sedgwick
Journal:  BMJ       Date:  2014-05-30

7.  Statistics and ethics in medical research: III How large a sample?

Authors:  D G Altman
Journal:  Br Med J       Date:  1980-11-15

8.  The continuing unethical conduct of underpowered clinical trials.

Authors:  Scott D Halpern; Jason H T Karlawish; Jesse A Berlin
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

9.  Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

Authors:  B J Materson; D J Reda; W C Cushman; B M Massie; E D Freis; M S Kochar; R J Hamburger; C Fye; R Lakshman; J Gottdiener
Journal:  N Engl J Med       Date:  1993-04-01       Impact factor: 91.245

10.  Why most published research findings are false.

Authors:  John P A Ioannidis
Journal:  PLoS Med       Date:  2005-08-30       Impact factor: 11.613

  10 in total
  4 in total

1.  Addressing partial identification in climate modeling and policy analysis.

Authors:  Charles F Manski; Alan H Sanstad; Stephen J DeCanio
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-13       Impact factor: 11.205

2.  Statistical Decision Properties of Imprecise Trials Assessing Coronavirus Disease 2019 (COVID-19) Drugs.

Authors:  Charles F Manski; Aleksey Tetenov
Journal:  Value Health       Date:  2021-03-09       Impact factor: 5.725

3.  Understanding and misunderstanding randomized controlled trials.

Authors:  Angus Deaton; Nancy Cartwright
Journal:  Soc Sci Med       Date:  2017-12-25       Impact factor: 5.379

4.  A 680,000-person megastudy of nudges to encourage vaccination in pharmacies.

Authors:  Katherine L Milkman; Linnea Gandhi; Mitesh S Patel; Heather N Graci; Dena M Gromet; Hung Ho; Joseph S Kay; Timothy W Lee; Jake Rothschild; Jonathan E Bogard; Ilana Brody; Christopher F Chabris; Edward Chang; Gretchen B Chapman; Jennifer E Dannals; Noah J Goldstein; Amir Goren; Hal Hershfield; Alex Hirsch; Jillian Hmurovic; Samantha Horn; Dean S Karlan; Ariella S Kristal; Cait Lamberton; Michelle N Meyer; Allison H Oakes; Maurice E Schweitzer; Maheen Shermohammed; Joachim Talloen; Caleb Warren; Ashley Whillans; Kuldeep N Yadav; Julian J Zlatev; Ron Berman; Chalanda N Evans; Rahul Ladhania; Jens Ludwig; Nina Mazar; Sendhil Mullainathan; Christopher K Snider; Jann Spiess; Eli Tsukayama; Lyle Ungar; Christophe Van den Bulte; Kevin G Volpp; Angela L Duckworth
Journal:  Proc Natl Acad Sci U S A       Date:  2022-02-08       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.